Samso News: Emyria Limited – Two-Thirds of PTSD Patients in Remission 12+ Months Post Treatment - Investors Take Note.
- Noel Ong
- 2 hours ago
- 7 min read
Announcement
Medibank Expands Funding to Emyria's Victorian Clinic - 16 February 2026 ( view announcement )
Emyria Expands Investor Access Into Europe - 12 February 2026 ( view announcement )
Emyria's PTSD Program Delivers Lasting Recovery – 2 February 2026 ( view the announcement )
The business of metal health is banking on this growing concern in the general population. The statistics for the general population in regards to some form of depression are staggering and I would bet that there would be easily be only one of two separation before you know someone needing help.
From a business point of view, any company would easily reap profits handsomely with some form of diagnosis or treatment of mental health. For Samso, we are ever keen to share and bring to a discussion any stories that would give investors some form of understanding.
Emyria Limited (ASX: EMD) is developing a data-driven mental health treatment platform through regulated clinical services in Australia. The Company combines specialist-led care delivery with real-world data collection to inform treatment protocols, payer engagement, and program scalability.
The latest 12+ month PTSD remission data provides long-term outcome visibility, which is a key reference point for assessing durability, reimbursement potential, and future program expansion.
Emyria Limited (ASX: EMD) – What the Company Does
Emyria Limited is an Australian healthcare company focused on developing and delivering new treatments for mental health and selected neurological conditions.
The Company operates through an integrated model with three core components:
Emyria Healthcare – Clinical Treatment Delivery
Emyria runs specialist-led clinics that provide evidence-based treatments to patients who have not found relief through conventional care.
This includes:
Treatment programs for Post-Traumatic Stress Disorder (PTSD)
Treatment programs for treatment-resistant depression
Delivery of therapies under Australia’s regulated access pathways
Care delivered under direct medical supervision
The focus is on severe or treatment-resistant patients.
Introducing Emyria Limited (ASX: EMD) - Durable PTSD Remission Data Demonstrates Sustained Clinical Outcomes at 12+ Months
The 2 February 2026 ASX Release provides updated long-term follow-up data from Emyria’s PTSD treatment program. The results reflect 12+ month post-treatment outcomes as at 31 December 2025 and build on previously reported 6-month data.
Emyria’s PTSD program focuses on patients with severe and long-standing symptoms who have failed multiple previous treatments. Symptom severity is measured using the internationally recognised PCL-5 scale.
The key outcome from this release is durability. Approximately two-thirds of patients who completed treatment and follow-up achieved remission, defined as a PCL-5 score of 32 or below (Figure 1). Around 76% experienced clinically significant improvements.
The data indicates:
Large symptom reductions by end of treatment
Sustained improvement at 12 months and beyond
No return to severe symptom levels
Continued improvement in some cases after active treatment ended
Figure 1: “Mean PTSD Symptom Scores Over Time (PCL-5)”This chart shows mean PCL-5 scores declining during active treatment and remaining below the clinical threshold (≤32) at 6-month and ≥12-month follow-up. The green shaded region highlights the remission threshold. (source EMD)
Importantly, the median time to remission was approximately 28 days from first treatment, with 50% of patients reaching remission within that timeframe and a further ~16% achieving remission during follow-up (Figure 2).
Routine safety monitoring during follow-up did not identify severe adverse reactions or safety concerns.
Figure 2: “Start vs End of Treatment vs 12-month+ Follow-up (PCL-5)”This figure presents matched data for 10 patients with complete assessments at baseline, end of treatment, and ≥12 months post-treatment, demonstrating sustained sub-clinical symptom levels.
The release also clarifies that patients who do not respond immediately continue to be followed. The protocol allows for evaluation of treatment indication markers and potential additional cycles or modified approaches.
Highlights – 12+ Month PTSD Program Outcomes and Program Expansion
Two-thirds of patients in remission at 12+ monthsPTSD symptom scores remain below the diagnostic threshold (PCL-5 ≤ 32), indicating sustained remission beyond one year.
~76% achieved clinically significant improvementDemonstrates meaningful symptom reduction across the treated cohort.
Median recovery time of ~28 days50% of patients reached remission within 28 days of starting treatment.
No severe adverse reactions identified in follow-up monitoringOngoing safety oversight has not identified severe concerns in the observed cohort.
More than 40 patients completed the PTSD program since inception (Nov 2023)
100+ patients screened and either in treatment or awaiting commencement (as at 31 December 2025)Demonstrates demand and forward pipeline.
67 additional patients booked for screening in Q1 CY2026
Private health insurer funding in placeIncreasing engagement from government-linked payers as long-term outcome data emerges.
The Company also contextualised PTSD prevalence, noting approximately 1 in 11 Australians experience PTSD during their lifetime, and over 17% of transitioned defence force veterans experience PTSD in a 12-month period.
Management Commentary
Medical Director Dr Jon Laugharne stated that two-thirds remission in a severe, treatment-resistant cohort represents clinically significant recovery. He noted that the durability suggests genuine recovery rather than temporary symptom suppression and confirmed that longitudinal outcome tracking is now being extended to depression programs.
Executive Chair Greg Hutchinson highlighted that durable and often immediate benefits are relevant not only to patients but also to practitioners and payers. He stated that the Company is building a data-driven platform supporting practitioner and patient acquisition and geographic expansion across a nationwide clinic network.
Near-term Milestones to Watch
Ongoing 12+ month follow-up data accumulation
Extension of longitudinal outcome framework into depression treatment program
Conversion of screened patients into active treatment cycles
Engagement with private and government-linked payers based on durability data
Scaling of clinic network and specialist-led service delivery
Samso Concluding Comments
This Samso News update is all about the path forward for Emyria Limited with the addition of the new practice in Victoria and the commencement of a structured European investor engagement program to expand international shareholder participation and awareness of the Company’s integrated, reimbursement-backed mental health clinical model.
Emyria Limited (ASX: EMD) key update focuses on long-term durability of the business in the results of their trials. The 12+ month remission data provides a measurable reference point for sustained outcomes in a treatment-resistant cohort. The use of the PCL-5 scale allows consistency in tracking clinical change over time.
The reported two-thirds remission rate, alongside a 76% clinically significant improvement rate, is based on real-world clinical data under regulated access pathways. The Company has clearly stated that the data is observational and not derived from a randomised controlled trial.
More than 100 patients have completed screening and are either receiving treatment or awaiting commencement, with additional screenings booked in Q1 CY2026. This suggests program utilisation is ongoing and structured.
From a systems perspective, from a business flow chart, the results all the potential realisation of connecting clinical durability with reimbursement potential. Long-term symptom reduction may reduce relapse, re-hospitalisation, and ongoing reliance on alternative treatments. The Company’s model integrates care delivery and real-world data generation as part of its broader mental health treatment platform.
Market Implication - The Investor Lens
One of the key aspect of the share price chart (Figure 3) is the engagement of the market with the news coming out from EMD. EMD has a current market capitalisation of just over AUD $47M which is reasonable for its stage. As a new advocate of this sector, I do think that this is still worth keeping an eye as it develops the potential of the business.
Figure3: The share price chart for EMD as of the 19th February 2026. (source: commsec).
I would love to get the company on a Coffee with Samso soon so that we can try and get the ins and outs of the business and get a real understanding of what we should know and look out for as retail investors. As I always say, DYOR.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.